• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    FibroBiologics to Present at the BIO International Convention 2025

    6/16/25 9:50:45 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FBLG alert in real time by email

    HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present a company update at the BIO International Convention 2025, June 16-19, 2025, in Boston, MA. The presentation will include recent corporate milestones and research advances using fibroblast-based technology for indications such as wound healing, multiple sclerosis, and psoriasis.

    "The BIO International Convention provides an ideal platform to showcase how FibroBiologics is potentially transforming the treatment landscape for chronic diseases," said Pete O'Heeron. "With our Phase 1/2 clinical trial in diabetic foot ulcers wound healing set to begin later this year, we are demonstrating that fibroblast-based therapies have the potential to address the underlying biological dysfunction rather than managing symptoms. This could represent a fundamental shift in how we approach the treatment of chronic diseases."

    Details of the presentation are as follows:

    Date: Tuesday, June 17, 2025

    Time: 10:45 a.m. ET

    Location: Boston Convention & Exhibition Center, Room 154

    To learn more about the event, please visit https://convention.bio.org/ or to schedule one-on-one meetings, please email [email protected].

    Cautionary Statement Regarding Forward-Looking Statements

    This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the timing of, clinical trials. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

    About FibroBiologics

    Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com. 

    General Inquiries:

    [email protected]

    Investor Relations:

    Nic Johnson

    Russo Partners

    (212) 845-4242

    [email protected]

    Media Contact:

    Liz Phillips

    Russo Partners

    (347) 956-7697

    [email protected]



    Primary Logo

    Get the next $FBLG alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FBLG

    DatePrice TargetRatingAnalyst
    12/12/2024$12.00Buy
    Rodman & Renshaw
    10/30/2024$12.00Buy
    H.C. Wainwright
    9/24/2024$12.00Buy
    Maxim Group
    More analyst ratings

    $FBLG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

      HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced it has closed the third $5 million tranche of the previously announced Standby Equity Purchase Agreement (the "SEPA") with YA II PN, Ltd. ("Yorkville"), an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell up to $25 million in the aggregate of its common stock to Yorkville over th

      6/16/25 4:35:00 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroBiologics to Present at the BIO International Convention 2025

      HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present a company update at the BIO International Convention 2025, June 16-19, 2025, in Boston, MA. The presentation will include recent corporate milestones and research advances using fibroblast-based technology for indications such as wound healing, multiple sclerosis, and psoriasis. "The BIO Interna

      6/16/25 9:50:45 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

      HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Jason D. Davis, CPA, as Chief Financial Officer, effective immediately. Mr. Davis brings extensive experience in corporate finance, capital markets, and SEC reporting, with a proven track record of successfully leading companies through critical growth phases, including IPOs and capital raising initiatives. His appointment comes as FibroBiologic

      6/9/25 8:30:00 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBLG
    SEC Filings

    See more
    • FibroBiologics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - FibroBiologics, Inc. (0001958777) (Filer)

      7/3/25 4:03:02 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroBiologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - FibroBiologics, Inc. (0001958777) (Filer)

      6/16/25 5:00:28 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroBiologics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - FibroBiologics, Inc. (0001958777) (Filer)

      6/13/25 4:00:26 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Niklas Victoria Ninon Olivia

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      6/12/25 7:30:37 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Link Matthew

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      6/12/25 7:26:50 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hoffman Robert E.

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      6/12/25 7:23:52 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBLG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on FibroBiologics with a new price target

      Rodman & Renshaw initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

      12/12/24 8:54:24 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on FibroBiologics with a new price target

      H.C. Wainwright initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

      10/30/24 6:37:36 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on FibroBiologics with a new price target

      Maxim Group initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

      9/24/24 7:59:12 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBLG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Khoja Hamid bought $16,800 worth of shares (20,000 units at $0.84), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      5/27/25 5:56:53 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer O'Heeron Pete bought $16,269 worth of shares (8,500 units at $1.91), increasing direct ownership by 0.14% to 6,056,647 units (SEC Form 4)

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      8/12/24 9:58:49 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Khoja Hamid bought $19,000 worth of shares (10,000 units at $1.90), increasing direct ownership by 800% to 11,250 units (SEC Form 4)

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      8/12/24 9:58:39 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBLG
    Leadership Updates

    Live Leadership Updates

    See more
    • FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

      HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Jason D. Davis, CPA, as Chief Financial Officer, effective immediately. Mr. Davis brings extensive experience in corporate finance, capital markets, and SEC reporting, with a proven track record of successfully leading companies through critical growth phases, including IPOs and capital raising initiatives. His appointment comes as FibroBiologic

      6/9/25 8:30:00 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroBiologics Set to Join Russell 2000® Index

      HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today it is set to join the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them b

      6/13/24 9:31:00 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroBiologics Appoints Ruben A. Garcia as General Counsel

      HOUSTON, March 6, 2024 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the appointment of Ruben A. Garcia as General Counsel. He will report to Pete O'Heeron, FibroBiologics' Founder, Chairman and Chief Executive Officer, and be an integral member of the executive leadership team.   "The addition of Ruben as our General Counsel rep

      3/6/24 9:31:00 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care